#1 Clinical Trials Search in Europe

Daptomycin

Daptomycin is an antibiotic used to treat various bacterial infections, particularly those caused by Gram-positive organisms. This article examines several clinical trials investigating the use of daptomycin in different patient populations and conditions, including prosthetic joint infections, endocarditis, and meningitis. These studies aim to evaluate the drug’s efficacy, safety, and pharmacokinetics in various clinical settings.

Table of Contents

What is Daptomycin?

Daptomycin, also known by its brand name Cubicin, is an antibiotic medication used to treat various bacterial infections[1]. It belongs to a class of drugs called cyclic lipopeptides, which are designed to combat difficult-to-treat bacterial infections[2]. Daptomycin is particularly effective against Gram-positive bacteria, including strains that have become resistant to other antibiotics like methicillin, vancomycin, or linezolid[3].

How Daptomycin Works

Daptomycin works differently from many other antibiotics. It binds to the membrane of Gram-positive bacteria and causes rapid depolarization of the membrane potential. This leads to bacterial cell death without causing the bacteria to break open (a process called lysis)[3]. This unique mechanism is important because it doesn’t release harmful bacterial components into the body, which can trigger excessive inflammation and potentially cause more damage[3].

Conditions Treated with Daptomycin

Daptomycin is used to treat a variety of bacterial infections, including:

  • Complicated skin and soft tissue infections: These are infections of the skin and underlying tissues that are severe or difficult to treat[4].
  • Bloodstream infections (bacteremia): This occurs when bacteria enter the bloodstream, potentially leading to serious complications[2].
  • Infective endocarditis: An infection of the inner lining of the heart chambers and valves[1].
  • Prosthetic joint infections: Infections that occur around artificial joints, such as hip, knee, or shoulder replacements[5].
  • Bacterial meningitis: An infection of the protective membranes covering the brain and spinal cord[3].

How Daptomycin is Administered

Daptomycin is typically given as an intravenous (IV) infusion, meaning it’s delivered directly into a vein[1]. The medication is usually administered once daily, with the infusion lasting about 30 minutes[6]. In some cases, it may be given as a subcutaneous injection (under the skin) if IV access is difficult[7].

Dosage Information

The dosage of daptomycin can vary depending on several factors, including the type and severity of the infection, the patient’s age, weight, and kidney function. Some common dosages include:

  • For adults: 4-6 mg/kg once daily for skin infections, and 6-8 mg/kg once daily for more serious infections like bacteremia or endocarditis[1][4].
  • For children: Dosages are typically weight-based and can range from 6-10 mg/kg once daily, depending on the child’s age[3].

Use in Special Populations

Daptomycin has been studied in various special populations:

  • Patients with kidney disease: Daptomycin can be used in patients undergoing hemodialysis or peritoneal dialysis, but dosage adjustments may be necessary[8][9].
  • Children: Studies have been conducted to determine appropriate dosing and safety in pediatric patients[3].
  • Surgical patients: Daptomycin has been investigated as a potential preventive antibiotic for patients undergoing heart surgery[6].

Potential Side Effects

Like all medications, daptomycin can cause side effects. Some potential side effects include:

  • Muscle effects: Daptomycin can cause muscle pain or weakness. Your doctor may monitor your blood levels of an enzyme called creatine phosphokinase (CPK) to check for muscle damage[10].
  • Kidney effects: In some cases, daptomycin may affect kidney function[1].
  • Local reactions: If given as a subcutaneous injection, there may be local reactions like pain, redness, or swelling at the injection site[7].

Ongoing Research and Future Applications

Research on daptomycin is ongoing, with studies exploring its use in various conditions and populations. Some areas of current research include:

  • Use in pediatric patients with bacterial meningitis[3].
  • Combination therapy with other antibiotics for difficult-to-treat infections[10].
  • Alternative routes of administration, such as subcutaneous injections[7].
  • Use as a preventive antibiotic in certain surgical procedures[6].

These ongoing studies aim to expand our understanding of daptomycin’s effectiveness and safety in various clinical scenarios, potentially leading to new applications and improved treatment strategies for bacterial infections.

Study Focus Key Findings Patient Population Administration Method
Subcutaneous vs. Intravenous Administration Investigating bioequivalence and safety of subcutaneous daptomycin Healthy volunteers Subcutaneous and intravenous
Hemodialysis Patients Comparing different dosing regimens during and after dialysis End-stage renal disease patients Intravenous
Pediatric Patients with Renal Disease Evaluating pharmacokinetics and safety in children on dialysis Children with chronic kidney disease Intravenous
Staphylococcal Endocarditis Assessing efficacy with and without gentamicin combination therapy Adults with infective endocarditis Intravenous
Prosthetic Joint Infections Investigating efficacy and safety with/without rifampin Adults with staphylococcal prosthetic joint infections Intravenous followed by oral antibiotics
Pediatric Bacterial Meningitis Evaluating cerebrospinal fluid penetration Children with Gram-positive bacterial meningitis Intravenous

FAQ

  • What is daptomycin? Daptomycin is an antibiotic used to treat infections caused by Gram-positive bacteria, including those resistant to other antibiotics like methicillin and vancomycin.
  • What types of infections can daptomycin treat? Clinical trials have investigated daptomycin for treating various infections, including prosthetic joint infections, endocarditis (heart valve infection), bloodstream infections, and meningitis (brain infection).
  • How is daptomycin administered? Daptomycin is typically given intravenously (through a vein). Some studies have also explored subcutaneous administration. The dosage and frequency depend on the specific condition being treated and the patient's characteristics.
  • Are there any side effects associated with daptomycin? Common side effects may include muscle pain or weakness, changes in kidney function, and elevated levels of certain enzymes. Clinical trials closely monitor patients for these and other potential adverse effects.
  • How does daptomycin compare to other antibiotics? Daptomycin has shown promise in treating infections caused by resistant bacteria. Some studies have compared it to standard treatments like vancomycin or explored its use in combination with other antibiotics to enhance effectiveness.

Ongoing Clinical Trials on Daptomycin

  • Comparing rifampin-free treatment versus rifampin in adults with staphylococcal prosthetic valve endocarditis

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on the Effectiveness of Clarithromycin and Other Drug Combinations for Patients with Uncomplicated Staphylococcus aureus Blood Infection

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Continuous vs. Intermittent Infusion of Ampicillin and Ceftriaxone for Patients with Enterococcus faecalis Infective Endocarditis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study Comparing Dalbavancin to Standard Antibiotics for Patients with Staphylococcus aureus Bloodstream Infections

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness of Moxifloxacin and Drug Combination for Treating Bone Implant Infections in Patients with Long Bone Fractures

    Recruiting

    3 1 1 1
    Investigated drugs:
    Spain

  • Study on the Effect of Rifampicin and Drug Combination for Patients with Staphylococcus aureus Bacteremia

    Recruiting

    3 1 1 1
    Investigated drugs:
    France Germany The Netherlands Sweden

  • Study on Shortened Antibiotic Treatment for Infectious Endocarditis Using Vancomycin, Meropenem, and Ceftriaxone for Patients with Left-Sided Heart Infection

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study comparing 3-week versus 6-week antibiotic treatment for patients with drained pyogenic liver abscess

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study of antibiotic treatment effectiveness in critically ill patients receiving drug combination therapy

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on the Impact of Cefepime, Piperacillin-Tazobactam, and Ceftobiprole on Gut Health in Patients with Bone and Joint Infections on Implants

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Gram-positive bacteria: A type of bacteria that retain a purple stain when subjected to a laboratory staining method. Many common disease-causing bacteria are Gram-positive, including Staphylococcus and Enterococcus species.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. This helps determine appropriate dosing and administration methods.
  • Endocarditis: An infection of the inner lining of the heart chambers and valves, often caused by bacteria entering the bloodstream.
  • Prosthetic joint infection: An infection that occurs around artificial joint implants, such as hip or knee replacements, which can be difficult to treat due to biofilm formation on the implant surface.
  • Meningitis: Inflammation of the protective membranes covering the brain and spinal cord, often caused by bacterial or viral infections.
  • Bactericidal: Capable of killing bacteria, as opposed to just inhibiting their growth.
  • Bioequivalence: The property of two drug formulations having the same biological effect and availability in the body.
  • Cerebrospinal fluid (CSF): The clear, colorless fluid that surrounds the brain and spinal cord, protecting them and helping to distribute nutrients and remove waste.
  • Methicillin-resistant Staphylococcus aureus (MRSA): A type of bacteria resistant to certain antibiotics, making infections more difficult to treat.
  • Subcutaneous: Beneath the skin. In medical contexts, it often refers to injections given into the fatty tissue just under the skin.

References

  1. https://clinicaltrials.gov/study/NCT00638157
  2. https://clinicaltrials.gov/study/NCT00467272
  3. https://clinicaltrials.gov/study/NCT01522105
  4. https://clinicaltrials.gov/study/NCT00651131
  5. https://clinicaltrials.gov/study/NCT01144000
  6. https://clinicaltrials.gov/study/NCT00701636
  7. https://clinicaltrials.gov/study/NCT04434300
  8. https://clinicaltrials.gov/study/NCT00882557
  9. https://clinicaltrials.gov/study/NCT01012089
  10. https://clinicaltrials.gov/study/NCT00401960